X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB GLENMARK PHARMA UNICHEM LAB/
GLENMARK PHARMA
 
P/E (TTM) x 21.8 13.6 160.1% View Chart
P/BV x 2.3 3.8 60.2% View Chart
Dividend Yield % 0.8 0.3 248.4%  

Financials

 UNICHEM LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
GLENMARK PHARMA
Mar-16
UNICHEM LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3341,262 26.5%   
Low Rs174672 25.9%   
Sales per share (Unadj.) Rs146.9270.6 54.3%  
Earnings per share (Unadj.) Rs11.924.9 47.8%  
Cash flow per share (Unadj.) Rs16.234.4 47.0%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.2 380.6%  
Book value per share (Unadj.) Rs105.1151.3 69.5%  
Shares outstanding (eoy) m90.84282.16 32.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.73.6 48.4%   
Avg P/E ratio x21.438.9 55.0%  
P/CF ratio (eoy) x15.728.1 55.9%  
Price / Book Value ratio x2.46.4 37.8%  
Dividend payout %16.88.0 209.2%   
Avg Mkt Cap Rs m23,073272,778 8.5%   
No. of employees `0005.710.0 56.6%   
Total wages/salary Rs m2,55813,782 18.6%   
Avg. sales/employee Rs Th2,352.57,614.9 30.9%   
Avg. wages/employee Rs Th450.91,374.8 32.8%   
Avg. net profit/employee Rs Th190.4700.2 27.2%   
INCOME DATA
Net Sales Rs m13,34676,340 17.5%  
Other income Rs m192356 53.9%   
Total revenues Rs m13,53876,696 17.7%   
Gross profit Rs m1,63914,172 11.6%  
Depreciation Rs m3902,691 14.5%   
Interest Rs m291,789 1.6%   
Profit before tax Rs m1,41210,048 14.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-40-   
Extraordinary Inc (Exp) Rs m-350-   
Tax Rs m2933,028 9.7%   
Profit after tax Rs m1,0807,019 15.4%  
Gross profit margin %12.318.6 66.2%  
Effective tax rate %20.730.1 68.8%   
Net profit margin %8.19.2 88.0%  
BALANCE SHEET DATA
Current assets Rs m5,97959,096 10.1%   
Current liabilities Rs m2,43240,018 6.1%   
Net working cap to sales %26.625.0 106.4%  
Current ratio x2.51.5 166.5%  
Inventory Days Days6375 84.1%  
Debtors Days Days60119 50.7%  
Net fixed assets Rs m6,40339,075 16.4%   
Share capital Rs m182282 64.4%   
"Free" reserves Rs m9,29330,281 30.7%   
Net worth Rs m9,54842,703 22.4%   
Long term debt Rs m23024,873 0.9%   
Total assets Rs m12,843111,026 11.6%  
Interest coverage x50.06.6 756.1%   
Debt to equity ratio x00.6 4.1%  
Sales to assets ratio x1.00.7 151.1%   
Return on assets %8.67.9 108.9%  
Return on equity %11.316.4 68.8%  
Return on capital %14.317.5 81.8%  
Exports to sales %29.243.3 67.5%   
Imports to sales %6.37.4 85.4%   
Exports (fob) Rs m3,90033,044 11.8%   
Imports (cif) Rs m8475,672 14.9%   
Fx inflow Rs m4,35636,945 11.8%   
Fx outflow Rs m1,16261,066 1.9%   
Net fx Rs m3,194-24,122 -13.2%   
CASH FLOW
From Operations Rs m1,1193,449 32.5%  
From Investments Rs m-853-8,802 9.7%  
From Financial Activity Rs m-3346,986 -4.8%  
Net Cashflow Rs m-68934 -7.3%  

Share Holding

Indian Promoters % 50.1 48.3 103.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 6.9 218.8%  
FIIs % 3.0 34.4 8.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 10.5 301.9%  
Shareholders   20,176 56,727 35.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare UNICHEM LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Aug 23, 2017 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - GLENMARK PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS